http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jul 2026 17:00:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/IPOs/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html <p>Scribe Therapeutics, a biotechnology company, has filed for an initial public offering (IPO) on the Nasdaq Global Market, revealing its intent to go public under the ticker symbol "SCTX." The company has submitted a registration statement but has not yet disclosed the number of shares to be offered or the expected price range, with placeholder values listed in the filing. Currently, no public market exists for Scribe's common stock, and the closing of the offering is contingent upon the company meeting Nasdaq's listing standards.</p><p>Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are serving as underwriters.</p> http://www.streetinsider.com/IPOs/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html Fri, 10 Jul 2026 17:00:14 -0400 SCTX http://www.streetinsider.com/Corporate+News/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html <p>Scribe Therapeutics, a biotechnology company, has filed for an initial public offering (IPO) on the Nasdaq Global Market, revealing its intent to go public under the ticker symbol "SCTX." The company has submitted a registration statement but has not yet disclosed the number of shares to be offered or the expected price range, with placeholder values listed in the filing. Currently, no public market exists for Scribe's common stock, and the closing of the offering is contingent upon the company meeting Nasdaq's listing standards.</p><p>Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are serving as underwriters.</p> http://www.streetinsider.com/Corporate+News/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html Fri, 10 Jul 2026 17:00:14 -0400 SCTX http://www.streetinsider.com/Hot+Corp.+News/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html <p>Scribe Therapeutics, a biotechnology company, has filed for an initial public offering (IPO) on the Nasdaq Global Market, revealing its intent to go public under the ticker symbol "SCTX." The company has submitted a registration statement but has not yet disclosed the number of shares to be offered or the expected price range, with placeholder values listed in the filing. Currently, no public market exists for Scribe's common stock, and the closing of the offering is contingent upon the company meeting Nasdaq's listing standards.</p><p>Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are serving as underwriters.</p> http://www.streetinsider.com/Hot+Corp.+News/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html Fri, 10 Jul 2026 17:00:14 -0400 SCTX http://www.streetinsider.com/Hot+IPOs/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html <p>Scribe Therapeutics, a biotechnology company, has filed for an initial public offering (IPO) on the Nasdaq Global Market, revealing its intent to go public under the ticker symbol "SCTX." The company has submitted a registration statement but has not yet disclosed the number of shares to be offered or the expected price range, with placeholder values listed in the filing. Currently, no public market exists for Scribe's common stock, and the closing of the offering is contingent upon the company meeting Nasdaq's listing standards.</p><p>Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are serving as underwriters.</p> http://www.streetinsider.com/Hot+IPOs/Scribe+Therapeutics+Files+for+Nasdaq+IPO/26757891.html Fri, 10 Jul 2026 17:00:14 -0400 SCTX http://www.streetinsider.com/Hot+Corp.+News/Scribe+Therapeutics+files+for+proposed+Nasdaq+IPO/26728937.html (Updated - July 2, 2026 4:49 PM EDT) <p>Scribe Therapeutics on Thursday filed for a proposed Nasdaq IPO.</p><p>The company describes itself as: "We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular http://www.streetinsider.com/Hot+Corp.+News/Scribe+Therapeutics+files+for+proposed+Nasdaq+IPO/26728937.html Thu, 02 Jul 2026 16:49:51 -0400 SCTX http://www.streetinsider.com/IPOs/Scribe+Therapeutics+files+for+proposed+Nasdaq+IPO/26728937.html (Updated - July 2, 2026 4:49 PM EDT) <p>Scribe Therapeutics on Thursday filed for a proposed Nasdaq IPO.</p><p>The company describes itself as: "We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular http://www.streetinsider.com/IPOs/Scribe+Therapeutics+files+for+proposed+Nasdaq+IPO/26728937.html Thu, 02 Jul 2026 16:49:51 -0400 SCTX http://www.streetinsider.com/Corporate+News/Scribe+Therapeutics+files+for+proposed+Nasdaq+IPO/26728937.html (Updated - July 2, 2026 4:49 PM EDT) <p>Scribe Therapeutics on Thursday filed for a proposed Nasdaq IPO.</p><p>The company describes itself as: "We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular http://www.streetinsider.com/Corporate+News/Scribe+Therapeutics+files+for+proposed+Nasdaq+IPO/26728937.html Thu, 02 Jul 2026 16:49:51 -0400 SCTX